Prior to the listing, Cessatech conducted a successful IPO of units which provided the Company with approx. DKK 15.8 million (before issue costs) and approx. 1,270 new shareholders. The issue funds will primarily finance the completion of the late stage development program for Cessatech’s lead asset CT001, approved by the European Medicines Agency. The issue of units is registered with Erhvervsstyrelsen and the total number of shares in Cessatech is 3,680,000 and the share capital amounts to DKK 736,000. In addition, a total of 2,520,000 warrants of series
TO 1 have been issued. Each warrant of series TO 1 entitles the holder the right to subscribe for one (1) new share in Cessatech at a subscription price of DKK 10.00 per share during the exercise period 15 November 2021 until 16 December 2021.

Tomorrow, the 16^th of December 2020 is the first day of trading in Cessatech’s shares and warrants of series TO 1 on Spotlight Stock Market. The shares will be traded under the ticker "CESSA" with ISIN DK0061411964 and the warrants of series TO 1 will be traded under the ticker "CESSA TO 1" with ISIN DK0061416849. Shareholders are welcome to attend the listing ceremony, which due to the Covid-19 pandemic will be held digitally through a live webcast.

Schedule

08:45 Ceremony starts and trading system introduction
08:46 An online welcome from Spotlight Stock Market followed by an interview with Jes Trygved, CEO.
08:59 Count-down
09:00 Share is listed
09:01 Thank you by Jes Trygved, CEO

The number of participants is limited to 350. Those who want to attend the listing ceremony are asked to register with Eventbrite using the following link before 8:00 am on the listing day, 16 December 2020: https://www.eventbrite.com/e/cessatechs-virtual-listing-ceremony-tickets-132301905561

The listing ceremony will be held in English.

For more information about Cessatech, please contact:

Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is expected to enter late stage clinical development in 2021.

Introduction video: https://cessatech.com/wp-content/uploads/2020/11/CessatechTeaser1_LR.mp4